ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Oxular Limited

Oxular Limited is an active company incorporated on 27 November 2014 with the registered office located in Uxbridge, Greater London. Oxular Limited was registered 11 years ago.
Status
Active
Active since incorporation
Company No
09331313
Private limited company
Age
11 years
Incorporated 27 November 2014
Size
Micro
Turnover is under £1M
Balance sheet is under £500,000
Under 10 employees
Confirmation
Submitted
Dated 19 November 2025 (22 days ago)
Next confirmation dated 19 November 2026
Due by 3 December 2026 (11 months remaining)
Last change occurred 20 days ago
Accounts
Submitted
For period 1 Nov31 Oct 2024 (1 year)
Accounts type is Total Exemption Full
Next accounts for period 31 December 2025
Due by 30 September 2026 (9 months remaining)
Address
The Charter Building
Vine Street
Uxbridge
Middlesex
UB8 1JG
England
Address changed on 20 Nov 2025 (21 days ago)
Previous address was 5th Floor Halo Counterslip Bristol BS1 6AJ United Kingdom
Telephone
01865636200
Email
Unreported
Website
People
Officers
2
Shareholders
1
Controllers (PSC)
1
Director • Senior Vice President • American • Lives in United States • Born in Jul 1972
Director • Senior Vice President • American • Lives in United States • Born in Aug 1977
Regeneron Pharmaceuticals, INC
PSC
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Regeneron UK Limited
Zoran Berkovic and Mark Volpe are mutual people.
Active
Oxular Acquisitions Limited
Zoran Berkovic and Mark Volpe are mutual people.
Active
Brands
Oxular
Oxular develops drug/device combination treatments for retinal disorders.
Financials
Net Assets, Total Assets & Total Liabilities (2016–2024)
Period Ended
31 Oct 2024
For period 31 Oct31 Oct 2024
Traded for 12 months
Cash in Bank
£1.33M
Decreased by £5.67M (-81%)
Turnover
Unreported
Decreased by £887K (-100%)
Employees
8
Decreased by 18 (-69%)
Total Assets
£2.59M
Decreased by £7.4M (-74%)
Total Liabilities
-£9.31M
Decreased by £121K (-1%)
Net Assets
-£6.72M
Decreased by £7.28M (-1302%)
Debt Ratio (%)
359%
Increased by 264.61% (+280%)
Latest Activity
Confirmation Submitted
20 Days Ago on 21 Nov 2025
Inspection Address Changed
21 Days Ago on 20 Nov 2025
Full Accounts Submitted
3 Months Ago on 20 Aug 2025
Shares Cancelled
11 Months Ago on 9 Jan 2025
Own Shares Purchased
11 Months Ago on 9 Jan 2025
Accounting Period Extended
11 Months Ago on 3 Jan 2025
Registered Address Changed
11 Months Ago on 3 Jan 2025
Regeneron Pharmaceuticals, Inc. (PSC) Appointed
11 Months Ago on 20 Dec 2024
Christina Takke Resigned
11 Months Ago on 20 Dec 2024
Zoran Berkovic Appointed
11 Months Ago on 20 Dec 2024
Get Credit Report
Discover Oxular Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Confirmation statement made on 19 November 2025 with updates
Submitted on 21 Nov 2025
Register inspection address has been changed from 5th Floor Halo Counterslip Bristol BS1 6AJ United Kingdom to The Charter Building Vine Street Charter Place Uxbridge UB8 1JG
Submitted on 20 Nov 2025
Total exemption full accounts made up to 31 October 2024
Submitted on 20 Aug 2025
Cancellation of shares. Statement of capital on 20 December 2024
Submitted on 9 Jan 2025
Purchase of own shares.
Submitted on 9 Jan 2025
Withdrawal of a person with significant control statement on 6 January 2025
Submitted on 6 Jan 2025
Notification of Regeneron Pharmaceuticals, Inc. as a person with significant control on 20 December 2024
Submitted on 6 Jan 2025
Termination of appointment of Mark William-Semrau Gaffney as a director on 20 December 2024
Submitted on 3 Jan 2025
Termination of appointment of Dmitrij Hristodorov as a director on 20 December 2024
Submitted on 3 Jan 2025
Termination of appointment of Rafiq Hasan as a director on 20 December 2024
Submitted on 3 Jan 2025
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year